{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:47:46Z","timestamp":1782809266323,"version":"3.54.5"},"reference-count":28,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:00:00Z","timestamp":1770508800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["101095052"],"award-info":[{"award-number":["101095052"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["40-00703-97-19069"],"award-info":[{"award-number":["40-00703-97-19069"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["9120012110075"],"award-info":[{"award-number":["9120012110075"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101095052"],"award-info":[{"award-number":["101095052"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018693","name":"Horizon Europe","doi-asserted-by":"publisher","award":["101080711"],"award-info":[{"award-number":["101080711"]}],"id":[{"id":"10.13039\/100018693","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.ard.2026.02.005","type":"journal-article","created":{"date-parts":[[2026,3,8]],"date-time":"2026-03-08T11:34:53Z","timestamp":1772969693000},"page":"1218-1228","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials"],"prefix":"10.1016","volume":"85","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1316-8035","authenticated-orcid":false,"given":"Yasuo","family":"Nagafuchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tjardo D.","family":"Maarseveen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristina","family":"Lend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rudin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjorn","family":"Gudbjornsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Nordstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Espen A.","family":"Haavardsholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdur","family":"Gr\u00f6ndal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon","family":"Lampa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kim H\u00f8rslev","family":"Petersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte Schrumpf","family":"Heiberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merete Lund","family":"Hetland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Nurmohamed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikkel","family":"\u00d8stergaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronald","family":"van Vollenhoven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Uhlig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuulikki","family":"Sokka-Isler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik B.","family":"van den Akker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom W.J.","family":"Huizinga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sytske Anne","family":"Bergstra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Knevel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0001","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0002","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13075-017-1266-4","article-title":"Poor prognostic factors guiding treatment decisions in rheumatoid arthritis patients: a review of data from randomized clinical trials and cohort studies","volume":"19","author":"Albrecht","year":"2017","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.005_bib0003","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.jbspin.2018.03.018","article-title":"Predictors of treatment response in rheumatoid arthritis","volume":"86","author":"Lequerr\u00e9","year":"2019","journal-title":"Jt Bone Spine"},{"issue":"2","key":"10.1016\/j.ard.2026.02.005_bib0004","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1136\/ard.62.2.120","article-title":"Anticitrullinated protein\/peptide antibody assays in early rheumatoid arthritis for predicting five year radiographic damage","volume":"62","author":"Meyer","year":"2003","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.ard.2026.02.005_bib0005","doi-asserted-by":"crossref","first-page":"R949","DOI":"10.1186\/ar1767","article-title":"Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis","volume":"7","author":"van der Helm-van Mil","year":"2005","journal-title":"Arthritis Res Ther"},{"issue":"2","key":"10.1016\/j.ard.2026.02.005_bib0006","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1093\/rheumatology\/keae113","article-title":"The impact of autoantibodies on the efficacy of biological disease-modifying anti-rheumatic drugs in rheumatoid arthritis: meta-analysis of randomized controlled trials","volume":"64","author":"Takase-Minegishi","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.ard.2026.02.005_bib0007","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1002\/art.27584","article-title":"2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"62","author":"Aletaha","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.ard.2026.02.005_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2024-004382","article-title":"Are poor prognostic factors a realistic basis for treatment decisions in patients with rheumatoid arthritis? Lessons from the IMPROVED study","volume":"10","author":"van der Pol","year":"2024","journal-title":"RMD Open"},{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0009","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41746-025-01997-1","article-title":"Location and amount of joint involvement differentiates rheumatoid arthritis into different clinical subsets","volume":"8","author":"Maarseveen","year":"2025","journal-title":"NPJ Digit Med"},{"key":"10.1016\/j.ard.2026.02.005_bib0010","doi-asserted-by":"crossref","first-page":"m4328","DOI":"10.1136\/bmj.m4328","article-title":"Active conventional treatment and three different biological treatments in early rheumatoid arthritis: phase IV investigator initiated, randomised, observer blinded clinical trial","volume":"371","author":"Hetland","year":"2020","journal-title":"BMJ"},{"issue":"11","key":"10.1016\/j.ard.2026.02.005_bib0011","doi-asserted-by":"crossref","first-page":"3381","DOI":"10.1002\/art.21405","article-title":"Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial","volume":"52","author":"Goekoop-Ruiterman","year":"2005","journal-title":"Arthritis Rheum"},{"issue":"10","key":"10.1016\/j.ard.2026.02.005_bib0012","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1136\/ard-2023-224116","article-title":"Certolizumab pegol, abatacept, tocilizumab or active conventional treatment in early rheumatoid arthritis: 48-week clinical and radiographic results of the investigator-initiated randomised controlled NORD-STAR trial","volume":"82","author":"\u00d8stergaard","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.ard.2026.02.005_bib0013","doi-asserted-by":"crossref","first-page":"523","DOI":"10.7326\/M15-0919","article-title":"Long-term outcomes of patients with recent-onset rheumatoid arthritis after 10 years of tight controlled treatment: a randomized trial","volume":"164","author":"Markusse","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ard.2026.02.005_bib0014","doi-asserted-by":"crossref","DOI":"10.7717\/peerj.11414","article-title":"partR2: partitioning R2 in generalized linear mixed models","volume":"9","author":"Stoffel","year":"2021","journal-title":"PeerJ"},{"issue":"10","key":"10.1016\/j.ard.2026.02.005_bib0015","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1002\/acr.22606","article-title":"Determining the minimally important difference in the clinical disease activity index for improvement and worsening in early rheumatoid arthritis patients","volume":"67","author":"Curtis","year":"2015","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0016","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/ard.2003.019935","article-title":"Pain and joint mobility explain individual subdimensions of the health assessment questionnaire (HAQ) disability index in patients with rheumatoid arthritis","volume":"64","author":"H\u00e4kkinen","year":"2005","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.ard.2026.02.005_bib0017","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1093\/rheumatology\/kel021","article-title":"Fatigue in rheumatoid arthritis reflects pain, not disease activity","volume":"45","author":"Pollard","year":"2006","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0018","doi-asserted-by":"crossref","first-page":"R8","DOI":"10.1186\/ar2907","article-title":"Levels of anti-citrullinated protein antibodies and IgM rheumatoid factor are not associated with outcome in early arthritis patients: a cohort study","volume":"12","author":"Ursum","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ard.2026.02.005_bib0019","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/ard-2024-226024","article-title":"Association of rheumatoid factor, anti-citrullinated protein antibodies and shared epitope with clinical response to initial treatment in patients with early rheumatoid arthritis: data from a randomised controlled trial","volume":"83","author":"Lend","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.ard.2026.02.005_bib0020","doi-asserted-by":"crossref","first-page":"508","DOI":"10.3899\/jrheum.080724","article-title":"The influence of sex on patients with rheumatoid arthritis in a large observational cohort","volume":"36","author":"Iikuni","year":"2009","journal-title":"J Rheumatol"},{"issue":"1","key":"10.1016\/j.ard.2026.02.005_bib0021","doi-asserted-by":"crossref","first-page":"R7","DOI":"10.1186\/ar2591","article-title":"Women, men, and rheumatoid arthritis: analyses of disease activity, disease characteristics, and treatments in the QUEST-RA study","volume":"11","author":"Sokka","year":"2009","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.ard.2026.02.005_bib0022","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1002\/acr.21762","article-title":"Significance of sex in achieving sustained remission in the consortium of rheumatology researchers of North America cohort of rheumatoid arthritis patients","volume":"64","author":"Jawaheer","year":"2012","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"10","key":"10.1016\/j.ard.2026.02.005_bib0023","doi-asserted-by":"crossref","first-page":"e688","DOI":"10.1016\/S2665-9913(22)00186-2","article-title":"Sex differences in remission rates over 24 weeks among three different biological treatments compared to conventional therapy in patients with early rheumatoid arthritis (NORD-STAR): a post-hoc analysis of a randomised controlled trial","volume":"4","author":"Lend","year":"2022","journal-title":"Lancet Rheumatol"},{"issue":"33","key":"10.1016\/j.ard.2026.02.005_bib0024","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta5330","article-title":"Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives","volume":"5","author":"Brookes","year":"2001","journal-title":"Health Technol Assess"},{"issue":"10","key":"10.1016\/j.ard.2026.02.005_bib0025","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1016\/j.joca.2010.07.011","article-title":"Treatment with TNF-\u03b1 inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis","volume":"18","author":"G\u00fcler-Y\u00fcksel","year":"2010","journal-title":"Osteoarthritis Cartilage"},{"issue":"9","key":"10.1016\/j.ard.2026.02.005_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2019.07.091","article-title":"Molecular portraits of early rheumatoid arthritis identify clinical and treatment response phenotypes","volume":"28","author":"Lewis","year":"2019","journal-title":"Cell Rep"},{"issue":"7987","key":"10.1016\/j.ard.2026.02.005_bib0027","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41586-023-06708-y","article-title":"Deconstruction of rheumatoid arthritis synovium defines inflammatory subtypes","volume":"623","author":"Zhang","year":"2023","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ard.2026.02.005_bib0028","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1136\/annrheumdis-2018-214539","article-title":"Synovial cellular and molecular signatures stratify clinical response to csDMARD therapy and predict radiographic progression in early rheumatoid arthritis patients","volume":"78","author":"Humby","year":"2019","journal-title":"Ann Rheum Dis"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000804?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726000804?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T08:33:56Z","timestamp":1782808436000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726000804"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":28,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["S0003496726000804"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.005","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Hand-dominant joint involvement pattern associates with favourable, and polyarthritis with unfavourable, treatment response to both csDMARDs and bDMARDs in early rheumatoid arthritis: a combined analysis of NORD-STAR and BeSt trials","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.02.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier B.V. on behalf of European Alliance of Associations for Rheumatology (EULAR).","name":"copyright","label":"Copyright"}]}}